OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+23.8%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$239M
AUM Growth
+$239M
(+19%)
Cap. Flow
+$5.52M
Cap. Flow
% of AUM
2.31%
Top 10 Holdings %
Top 10 Hldgs %
60.96%
Holding
53
New
9
Increased
16
Reduced
7
Closed
12
Top Buys
| 1 |
CORI
Corium International, Inc.
CORI
|
$4.13M |
| 2 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$3.04M |
| 3 |
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
|
$2.95M |
| 4 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
$2.87M |
| 5 |
Ardelyx
ARDX
|
$2.79M |
Top Sells
| 1 |
TVRD
Tvardi Therapeutics, Inc. Common Stock
TVRD
|
$7.08M |
| 2 |
Ocular Therapeutix
OCUL
|
$5.1M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$3.2M |
| 4 |
GNMX
Aevi Genomic Medicine, Inc.
GNMX
|
$1.99M |
| 5 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
$1.96M |
Sector Composition
| 1 | Healthcare | 91.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BPMC
1
DELISTED
Blueprint Medicines
BPMC
| $44.6M | 18.63% | 880,000 | – | – |
|
2
Axogen
AXGN
$743M
| $33M | 13.78% | 1,970,000 | – | – |
|
3
FibroGen
FGEN
$47.8M
| $11.6M | 4.86% | 360,000 +30,000 | +9% | +$969K |
|
|
LOXO
4
DELISTED
Loxo Oncology, Inc
LOXO
| $10.4M | 4.35% | 130,000 | – | – |
|
|
SBBP
5
DELISTED
Strongbridge Biopharma plc.
SBBP
| $8.44M | 3.52% | 1,180,000 | – | – |
|
6
Codexis
CDXS
$246M
| $8.01M | 3.35% | 1,470,000 +300,000 | +26% | +$1.63M |
|
|
IMMU
7
DELISTED
Immunomedics Inc
IMMU
| $7.95M | 3.32% | 900,000 -60,000 | -6% | -$530K |
|
|
MNTA
8
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $7.61M | 3.18% | 450,000 +10,000 | +2% | +$169K |
|
9
Theravance Biopharma
TBPH
$699M
| $7.17M | 3% | 180,000 | – | – |
|
10
CytomX Therapeutics
CTMX
$336M
| $7.13M | 2.98% | 460,000 +120,000 | +35% | +$1.86M |
|
|
CMRX
11
DELISTED
Chimerix, Inc.
CMRX
| $6.98M | 2.91% | 1,280,000 +65,000 | +5% | +$354K |
|
|
NVLN
12
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| $6.92M | 2.89% | 750,000 +20,000 | +3% | +$185K |
|
13
Agios Pharmaceuticals
AGIO
$2.19B
| $6.69M | 2.79% | 130,000 | – | – |
|
|
CORI
14
DELISTED
Corium International, Inc.
CORI
| $5.33M | 2.23% | 715,000 +553,000 | +341% | +$4.13M |
|
|
FOMX
15
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $5.27M | 2.2% | 1,135,000 +635,000 | +127% | +$2.95M |
|
16
Sangamo Therapeutics
SGMO
$157M
| $5.1M | 2.13% | 580,000 -1,000 | -0.2% | -$8.8K |
|
|
ADMS
17
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $5.07M | 2.12% | 290,000 | – | – |
|
|
EGRX
18
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $4.73M | 1.98% | 60,000 +10,000 | +20% | +$789K |
|
19
Prothena Corp
PRTA
$441M
| $4.6M | 1.92% | 85,000 -2,100 | -2% | -$114K |
|
20
Enanta Pharmaceuticals
ENTA
$180M
| $3.6M | 1.5% | 100,000 | – | – |
|
|
NDRM
21
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $3.6M | 1.5% | 120,300 +300 | +0.3% | +$8.97K |
|
|
XLRN
22
DELISTED
Acceleron Pharma Inc.
XLRN
| $3.04M | 1.27% | +100,000 | New | +$3.04M |
|
|
BOLD
23
DELISTED
Audentes Therapeutics, Inc
BOLD
| $2.87M | 1.2% | +150,000 | New | +$2.87M |
|
24
Harrow
HROW
$1.44B
| $2.86M | 1.2% | 895,000 +34,500 | +4% | +$110K |
|
|
25
Ardelyx
ARDX
$1.53B
| $2.79M | 1.16% | +546,500 | New | +$2.79M |
|